Frank Herringer - Amgen Independent Director
| AMGN34 Stock | BRL 48.95 0.63 1.30% |
Director
Mr. Frank C. Herringer is no longer a Director of Amgen Inc. Mr. Herringer is an Independent Director of Amgen Inc. Frank C. Herringer was a director of the Board of Transamerica Corporationrationration, a financial services company, since 1986, serving as Chairman of the board of directors from 1995 to December 2015. Mr. Herringer was an executive with Transamerica for 20 years, including its Chief Executive Officer from 1991 until its acquisition by Aegon N.V., a life insurance, pensions and asset management company, in 1999, subsequently serving on Aegons Executive Board for one year. Mr. Herringer was a director of Aegon U.S. Holding Corporation from 1999 until its merger into Transamerica Corporation in December 2015. Mr. Herringer was a director of The Charles Schwab Corporationrationration, a brokerage and banking company, since 1996, serving on its Compensation Committee and chairing its Nominating and Corporationrationrate Governance Committee. He is a member of the Board of Trustees of the California Pacific Medical Center Foundation, a notforprofit organization which develops philanthropic resources for the California Pacific Medical Center, a privatelyheld, notforprofit academic medical center, since 2013. He was a director of Safeway Inc., a food and drug retailer, from 2008 until 2015, serving on its Executive Compensation and Executive Committees and chairing its Nominating and Corporationrationrate Governance Committee since 2017.
| Age | 74 |
| Tenure | 7 years |
| Phone | 805 447 1000 |
| Web | https://www.amgen.com |
Amgen Management Efficiency
The company has return on total asset (ROA) of 0.0997 % which means that it generated a profit of $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.2647 %, meaning that it generated $1.2647 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Maynard Webb | salesforce inc | 62 | |
| Eugenio Stramosk | Metalrgica Riosulense SA | 52 | |
| Sanford Robertson | salesforce inc | 85 | |
| Susan Wojcicki | salesforce inc | 48 | |
| Alexandre Fialho | Metalfrio Solutions SA | N/A | |
| Parker Harris | salesforce inc | 56 | |
| John Roos | salesforce inc | 63 | |
| Eduardo Filho | Tres Tentos Agroindustrial | N/A | |
| Alan Hassenfeld | salesforce inc | 69 | |
| Colin Powell | salesforce inc | 79 | |
| Bernhard Volkmann | MAHLE Metal Leve | 65 | |
| Helio Beltrao | Metalfrio Solutions SA | N/A | |
| Robin Washington | salesforce inc | 55 | |
| Pedro Guerra | Metalfrio Solutions SA | N/A | |
| Heinz Junker | MAHLE Metal Leve | 65 | |
| Craig Conway | salesforce inc | 63 | |
| Bernard Tyson | salesforce inc | 58 | |
| Neelie Kroes | salesforce inc | 67 | |
| Carlos Leao | Metalfrio Solutions SA | N/A | |
| Mauro Arruda | MAHLE Metal Leve | 68 | |
Management Performance
| Return On Equity | 1.26 | |||
| Return On Asset | 0.0997 |
Amgen Inc Leadership Team
Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Louie, Vice President - Finance, Chief Accounting Officer | ||
| Frank Herringer, Independent Director | ||
| Nancy Grygiel, Sr Officer | ||
| Francois Carbonnel, Independent Director | ||
| Rebecca Henderson, Independent Director | ||
| Annette Such, Chief Accounting Officer | ||
| Sanders Williams, Independent Director | ||
| Vance Coffman, Lead Independent Director | ||
| David Reese, Executive Vice President - Research and Development | ||
| Tyler Jacks, Independent Director | ||
| Brian McNamee, Executive Vice President - Full Potential Initiatives | ||
| Gregory Garland, Independent Director | ||
| Charles Holley, Independent Director | ||
| Esteban Santos, Executive Vice President Operations | ||
| Jonathan Graham, Senior Vice President General Counsel, Secretary | ||
| Sean Harper, Executive Vice President - Research and Development | ||
| Mike Zahigian, VP Officer | ||
| Ellen Kullman, Independent Director | ||
| Frank Biondi, Independent Director | ||
| Arvind Sood, IR Contact Officer | ||
| David Meline, Executive Vice President, Chief Financial Officer | ||
| Ronald Sugar, Independent Director | ||
| Stuart Tross, Senior Vice President - Human Resources | ||
| Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee | ||
| Murdo Gordon, Executive Vice President of Global Commercial Operations | ||
| Peter Griffith, Chief Financial Officer, Executive Vice President | ||
| Wanda Austin, Independent Director | ||
| Robert Eckert, Lead Independent Director | ||
| Madhavan Balachandran, Executive VP of Operations | ||
| Lori Johnston, Senior Vice President - Human Resources | ||
| Brian Druker, Independent Director | ||
| Cynthia Patton, Senior Vice President Chief Compliance Officer | ||
| Greg Garland, Independent Director | ||
| Robert Williams, Independent Director | ||
| Amy Miles, Independent Director | ||
| Judith Pelham, Independent Director | ||
| David Baltimore, Independent Director | ||
| Fred Hassan, Independent Director | ||
| David Piacquad, Senior Vice President - Business Development | ||
| Anthony Hooper, Executive VP of Global Commercial Operations | ||
| David MD, Ex RD |
Amgen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.26 | |||
| Return On Asset | 0.0997 | |||
| Profit Margin | 0.25 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 910.32 B | |||
| Shares Outstanding | 14.95 B | |||
| Price To Earning | 0.83 X | |||
| Price To Book | 39.25 X | |||
| Price To Sales | 29.10 X | |||
| Revenue | 26.32 B |
Pair Trading with Amgen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.Moving together with Amgen Stock
| 0.72 | N1VS34 | Novartis AG | PairCorr |
Moving against Amgen Stock
| 0.83 | ITUB3 | Ita Unibanco Holding | PairCorr |
| 0.82 | TMCO34 | Toyota Motor | PairCorr |
| 0.79 | LILY34 | Eli Lilly | PairCorr |
| 0.77 | ITUB4 | Ita Unibanco Holding | PairCorr |
| 0.76 | TSMC34 | Taiwan Semiconductor | PairCorr |
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Amgen Inc information on this page should be used as a complementary analysis to other Amgen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Amgen Stock analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |